DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Powles T, Bellmunt J, Castellano D. et al.
170 - Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052.
Eur Urol 2017;
16: e285-e286
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.